Morphogenesis Inc. Acquires TυHURA Biopharma’s First-in-Class Antibody Drug Conjugates (ADCs) Technology Designed to Overcome Acquired Resistance to Cancer Immunotherapy
28. März 2023 08:45 ET
|
Morphogenesis Inc.
Proprietary bi-functional ADCs target and inhibit unique Delta receptor on tumor-associated Myeloid Derived Suppressor Cells (MDSCs); increasing tumor’s susceptibility to checkpoint inhibitors and...
Steadman Philippon Research Institute Receives Third NIH Grant
22. August 2019 13:46 ET
|
The Steadman Clinic and Steadman Philippon Research Institute
Vail, Colorado, Aug. 22, 2019 (GLOBE NEWSWIRE) -- The National Institutes of Health (NIH) awarded Steadman Philippon Research Institute (SPRI) a grant to study muscle-derived stem cells (MDSCs)...